Workflow
BITS
icon
Search documents
X @Bybit
Bybit· 2025-07-18 10:04
RT Bybit Alpha (@BybitAlpha)📣 $TA is coming soon to the #BybitSpot trading platform!@TrustaLabs is building a trusted ID network and credit system for both humans and AI in crypto and beyond.Stay tuned for more! https://t.co/uG9IuWrzVn ...
How reading shapes success | Saimon Sherwal | TEDxWestbourne Grammar Youth
TEDx Talks· 2025-07-15 16:27
Dr. . Zeus once said, "The more you read, the more things you will know, and the more you learn, the more places you'll go." Sounds simple, right. But now, let me ask you this.When was the last time you read a book that wasn't for school or for work. Exactly. Now, let me tell you about a man, James Clear.You might know him as the author of Atomic Habits, a book on proven ways to build good habits. Well, James wasn't always a best-selling author. Once he was just a guy with a broken face, literally, he had s ...
Verano Announces Promotion and Appointment of James Leventis as Chief Strategy and Compliance Officer
Globenewswire· 2025-07-15 11:00
CHICAGO, July 15, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the promotion and appointment of James Leventis as the Company’s Chief Strategy and Compliance Officer, effective as of July 1, 2025. As the newest member of Verano’s executive leadership team, Leventis will provide strategic leadership over the Company’s robust regulatory, licensing, compliance and government affairs activities ...
Better Quantum Computing Stock: D-Wave Quantum vs. IonQ
The Motley Fool· 2025-07-12 13:15
Core Insights - Quantum computers have the potential to revolutionize industries by performing complex calculations much faster than current supercomputers [1] - D-Wave Quantum and IonQ are two companies in the quantum computing sector that present intriguing investment opportunities, but their performance and strategies differ significantly [2] D-Wave Quantum - D-Wave's stock has increased over 90% in 2025, reaching a 52-week high of $19.77 in May, driven by a 509% year-over-year increase in Q1 revenue to $15 million, surpassing its total sales of $8.8 million for all of 2024 [4][5] - The revenue surge was attributed to the first sale of its proprietary Advantage quantum machine, shifting from a previous reliance on quantum computing as a service (QCaaS) [5] - D-Wave's Q1 operating loss improved to $11.3 million from $17.5 million in 2024, with total assets of $325.6 million, including $304.3 million in cash, and liabilities of $118.2 million [6] - The company has sufficient cash reserves, approximately $815 million after an equity offering, to sustain operations until profitability, with some funds allocated for acquisitions [7] IonQ - IonQ's stock performance has been less impressive, with a 9% increase through July 9, attributed to disappointing Q1 results [8] - Q1 revenue was flat at $7.6 million compared to 2024, while operating losses increased to $75.7 million from $52.9 million the previous year [9] - IonQ maintains a strong balance sheet with total Q1 assets of $850.1 million and liabilities of $85 million, and announced a $1 billion equity offering to bolster finances [10] - The company is focused on building a quantum computing network, which is costly and requires acquiring various capabilities, such as the recent acquisition of Lightsynq Technologies [11] Comparative Analysis - D-Wave claims to be the sole provider of both quantum gate technology and quantum annealing, while IonQ is pursuing a network-building strategy [12] - The long-term success of either company remains uncertain, with potential competition from larger players like Microsoft [13] - D-Wave's impressive Q1 results may not be sustainable, as they represent a shift from its traditional revenue model [14] - IonQ, despite a slow start in 2025, reported a 95% year-over-year revenue growth to $43.1 million by the end of 2024 and projects sales between $75 million and $95 million for 2025 [15] - Valuation metrics indicate that both D-Wave and IonQ have higher price-to-sales (P/S) ratios compared to Microsoft, suggesting potential overvaluation [16] Investment Strategy - Given the high valuations and uncertainty in the quantum computing sector, it may be prudent to wait for Q2 earnings reports to assess the sustainability of D-Wave's Q1 results and IonQ's recovery potential [18]
This Artificial Intelligence (AI) Stock Is Surging After Joining the S&P 500. Can It Continue to Skyrocket?
The Motley Fool· 2025-07-09 00:00
Shares of Datadog (DDOG -4.23%) shot up nearly 15% on July 3 after it was revealed that the provider of cloud-based observability, monitoring, and security solutions will join the S&P 500 index on July 9.Datadog will be replacing Juniper Networks in the index after the latter was acquired by Hewlett Packard Enterprise. It is easy to see why Datadog's inclusion in the index has sent its stock soaring. To enter the index, a company needs to demonstrate solid profitability in the past four quarters, along with ...
华人学者本周发表4篇Cell论文:高度血管化的肺/肠道类器官;修复血管性痴呆;自身免疫病新疗法;同义突变调控性状
生物世界· 2025-07-05 02:12
撰文丨王聪 编辑丨王多鱼 排版丨水成文 本周 (6 月 30-7 月 6 日) ,国际顶尖学术期刊 Cell 共上线了 5 篇研究论文,其中 4 篇来自华人学者,这些研究分别构建 高度血管化的 肺类器 官和肠道类器官 、 发现 血管性痴呆的大脑修复机制 、 开发 LAG-3/TCR双抗,治疗T细胞驱动的自身免疫病 、揭示 同义突变通过表观转录组调控 赋予黄瓜驯化性状 。 高度血管化的 肺类器官和肠道类器官 2025 年 6 月 30 日, 辛辛那提儿童医院/加州大学洛杉矶分校 顾名夏 团队和 辛辛那提儿童医院 郭敏哲 团队合作,在国际顶尖学术期刊 Cell 上发 表了题为: Co-development of Mesoderm and Endoderm Enables Organotypic Vascularization in Lung and Gut Organoids 的研究论文。 该研究 首次通过人类 诱导多能干细胞 (iPSC) 成功构建了 高度血管化的肺类器官和肠道类器官 。这些类器官模型不仅模拟了人类胚胎早期多胚层 协同发育的复杂过程,更突破了传统类器官缺乏功能性血管和器官特异性间充质的瓶颈,为 ...
Datadog's S&P 500 Debut Could Spark A Sizzling Rally
Benzinga· 2025-07-03 14:18
Datadog Inc. DDOG just secured its spot in the S&P 500 Index. And while the headlines are focused on the 10% surge during early trading on Thursday, Wedbush analyst Dan Ives sees a bigger story unfolding.This isn't just a ripple effect of rebalancing. It's a validation of Datadog's rising dominance in the AI-fueled observability game; the beginning of what could be a multi-quarter growth wave.Read Also: Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving PremarketS&P 500 Inclusion L ...
Datadog(DDOG.US)跻身标普500指数 获Wedbush上调目标价至170美元
Zhi Tong Cai Jing· 2025-07-03 13:39
Group 1 - Datadog has been included in the S&P 500 index, marking a significant milestone for the company [1][2] - Wedbush raised Datadog's target price from $140 to $170 per share, citing optimistic market prospects and reaffirming its industry-leading position [1] - The partnership with OpenAI is expected to create strategic synergies amid the global wave of generative AI technology applications [1] Group 2 - The inclusion of Datadog in the S&P 500 follows HPE's acquisition of Juniper Networks, leading to a re-evaluation of the value in the cloud-native observability sector [2] - This change reflects the rising trend of AI-driven enterprise services in the market [2] - Datadog's technological advancements, particularly in AI applications, have been highlighted as key factors for its selection over other candidates like Robinhood and Applovin [1]
Verano to Report Second Quarter 2025 Financial Results on August 7, 2025
Globenewswire· 2025-07-01 11:00
Company Overview - Verano Holdings Corp. is a leading multi-state cannabis company in the U.S., recognized for its historical revenue, geographic scope, and brand performance [2] - The company operates under the Zen Leaf and MÜV dispensary brands and offers an innovative membership program called Cabbage Club, providing exclusive benefits to cannabis consumers [2] - Verano has a comprehensive portfolio of high-quality cannabis products sold under various trusted consumer brands, including Verano, Essence, MÜV, Savvy, BITS, Encore, and Avexia [2] - The company operates in 13 U.S. states with 15 production facilities, boasting over 1.1 million square feet of cultivation capacity [2] Upcoming Financial Results - Verano plans to release its financial results for the second quarter ended June 30, 2025, before the market opens on August 7, 2025 [1] - A conference call and webcast for analysts and investors is scheduled for August 7, 2025, at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results and address questions [1][4]
Cell:王俊团队等开发新型LAG-3/TCR双抗,治疗T细胞驱动的自身免疫病
生物世界· 2025-07-01 04:04
撰文丨王聪 编辑丨王多鱼 排版丨水成文 自身免疫疾病 是由过度活跃的免疫反应导致组织损伤而引发的。目前已有许多疗法通过靶向细胞因子或 B 细胞来治疗自身免疫疾病 (例如,利用 CAR-T 细胞 靶向耗竭 B 细胞来治疗系统性红斑狼疮等自身免疫疾病) ,然而,T 细胞在诸如 1 型糖尿病、肝炎、多发性硬化症和类风湿性关节炎等许多疾病中也发挥着核心 作用。 T 细胞通过细胞毒性、细胞因子释放以及通过辅助性 T 细胞引导其他免疫细胞等方式参与疾病的发生发展。然而,广泛的 T 细胞抑制可能会导致免疫缺陷、癌症 以及机会性感染等风险。 因此,我们需要开发一种新疗法——能够选择性靶向自身反应性或致病性 T 细胞,同时保留有益的 T 细胞功能。 2025 年 6 月 30 日,纽约大学格罗斯曼医学院 王俊 教授 团队联合中国科学院生物物理研究所 娄继忠 研究员 团队、浙江大学医学院 陈伟 教授 团队 ( Jasper Du 、 陈辉 、 由佳 为共同第一作者 ) ,在国际顶尖学术期刊 Cell 发表了题为: Proximity between LAG-3 and the T Cell Receptor Guides Sup ...